Claims for Patent: 6,210,879

Summary for Patent: 6,210,879

Title:	Method for diagnosing schizophrenia
Abstract:	The present invention relates to a method for diagnosing schizophrenia, said method being based on the detection in vitro of the presence of the allele Ep of the microsatellite HUNTH01 in the gene TH. The invention also relates to the primers used for implementing said method.
Inventor(s):	Meloni; Rolando (Paris, FR), Laurent; Claudine (Saint Cloud, FR), Mallet; Jacques (Paris, FR)
Assignee:	Rhone-Poulenc Rorer S.A. (Antony Cedex, FR)
Application Number:	08/930,117
Patent Claims:	1. A method for diagnosing schizophrenia, comprising a) obtaining from a patient a DNA sample comprising the HUMTH01 microsatellite in the tyrosine hydroxylase (TH) gene; and b) identifying the HUMTH01 microsatellite allele present in the patient, wherein detection of a perfect allele (Ep) of the HUMTH01 microsatellite is an indication that said patient may suffer from schizophrenia. 2. The method according to claim 1, wherein the HUMTH01 microsatellite allele is detected by sequencing. 3. The method according to claim 1, wherein the HUMTH01 microsatellite allele is detected by gel separation. 4. The method according to claim 1, wherein the HUMTH01 microsatellite allele is detected by a single strand conformational polymorphism (SSCP) method. 5. The method according to claim 1, wherein the DNA is extracted from mononucleated cells of said patient. 6. The method according to claim 1, wherein the DNA is amplified prior to detection. 7. The method according to claim 6, wherein the amplified DNA comprises part of a first intron of the TH gene. 8. The method according to claim 6, wherein the amplified DNA is less than 300 bp in size, and comprises the HUMTH01 microsatellite and flanking sequences. 9. The method according to claim 8, wherein the amplified DNA is less than 200 bp in size. 10. The method according to claim 9, wherein the amplified DNA is less than 100 bp in size. 11. The method according to claim 1, further comprising diagnosing schizophrenia according to clinical criteria. 12. A method for demonstrating a predisposition to schizophrenia, comprising a) obtaining from a patient a DNA sample comprising the HUMTH01 microsatellite in the tyrosine hydroxylase (TH) gene; and b) identifying the HUMTH01 microsatellite allele present in the patient, wherein detection of a perfect allele (Ep) of the HUMTH01 microsatellite is an indication of a predisposition to schizophrenia in said patient. 13. The method according to claim 12, wherein the HUMTH01 microsatellite allele is detected by sequencing. 14. The method according to claim 12, wherein the HUMTH01 microsatellite allele is detected by gel separation. 15. The method according to claim 12, wherein the HUMTH01 microsatellite allele is detected by a single strand conformational polymorphism (SSCP) method. 16. The method according to claim 12, wherein the DNA is extracted from mononucleated cells of the patient. 17. The method according to claim 12, wherein the DNA is amplified prior to detection. 18. The method according to claim 17, wherein the amplified DNA comprises part of a first intron of the TH gene. 19. The method according to claim 17, wherein the amplified DNA is less than 300 bp in size, and comprises the HUMTH01 microsatellite and flanking sequences. 20. The method according to claim 19, wherein the amplified DNA is less than 200 bp in size. 21. The method according to claim 20, wherein the amplified DNA is less than 100 bp in size.

Details for Patent 6,210,879

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-05-03
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-05-03
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2015-05-03